XTEND-Kids 3期跨国试验中接受每周一次 efanesoctocog alfa 预防治疗的12岁以下重型A型血友病儿童出血事件与临床相关药代动力学参数的事后分析
XTEND-Kids 3期开放标签研究纳入12岁以下既往接受过治疗的儿童重型A型血友病患者,每周一次efanesoctocog alfa(50 IU/kg)预防治疗52周。事后分析显示,稳态下FVIII水平>40 IU/dL持续3天、>10 IU/dL持续约7天,64%的参与者零出血,单次给药解决95%的出血事件,97%的首次注射止血疗效评为优秀或良好,未报告抑制剂或意外安全性发现。
要点
- 每周一次efanesoctocog alfa(50 IU/kg)预防治疗使稳态FVIII>40 IU/dL持续3天、>10 IU/dL持续约7天。
- 64%的参与者实现零出血,自发性和创伤性出血事件每周发生率在整个52周研究期间持续较低。
- 单次给药解决95%的出血事件,97%的首次注射止血疗效评为优秀或良好,未报告抑制剂。
核心结论
- 每周一次efanesoctocog alfa预防治疗在12岁以下既往接受过治疗的儿童重型A型血友病患者中提供高持续FVIII水平和高效出血治疗与预防。
研究设计与样本
- XTEND-Kids(NCT04759131)是一项3期、开放标签研究,纳入12岁以下既往接受过治疗的儿童重型A型血友病患者,参与者接受每周一次efanesoctocog alfa(50 IU/kg)预防治疗52周。
- 本分析为事后分析,评估年化出血率、出血治疗、治疗反应、药代动力学和安全性结局(包括免疫原性)。
主要发现
- 稳态下,每周一次efanesoctocog alfa(50 IU/kg)预防治疗使FVIII水平在正常至接近正常范围(>40 IU/dL)持续3天,>10 IU/dL持续约7天。
- 药代动力学参数在血型O和非O参与者中相似。
- efanesoctocog alfa预防治疗实现有效出血保护,64%的参与者零出血,年化出血率持续较低。
- 自发性和创伤性出血事件每周发生率在整个52周研究期间持续较低。
- 单次剂量efanesoctocog alfa解决95%的出血事件,无论类型或部位;97%的评估首次注射止血疗效评为优秀或良好。
关键数值与推荐
- 稳态下FVIII>40 IU/dL持续3天,>10 IU/dL持续约7天。
- 64%的参与者零出血。
- 单次给药解决95%的出血事件。
- 97%的评估首次注射止血疗效评为优秀或良好。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Once-weekly efanesoctocog alfa (50 IU/kg) provided high-sustained factor (F)VIII activity and robust bleed protection in previously treated children with severe hemophilia A. OBJECTIVES: This post hoc analysis presents additional bleed treatment and pharmacokinetic (PK) outcomes from the XTEND-Kids study (NCT04759131). METHODS: XTEND-Kids was a phase 3, open-label study in previously treated children aged <12 years with severe hemophilia A. Participants received once-weekly efanesoctocog alfa (50 IU/kg) prophylaxis for 52 weeks. Annualized bleed rate, bleed treatment, response to treatment, PK, and safety outcomes, including immunogenicity, were assessed. RESULTS: Once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) provided high-sustained FVIII levels in the normal to near-normal range (>40 IU/dL) for 3 days and >10 IU/dL for approximately 7 days at steady state; PK parameters were similar in participants with blood groups O and non-O. Efanesoctocog alfa prophylaxis resulted in effective bleed protection with zero bleeds in 64% of participants and consistently low annualized bleed rates. The rate of spontaneous and traumatic bleeding episodes per week remained consistently low throughout the 52-week study period. A single dose of efanesoctocog alfa resolved 95% of bleeding episodes, regardless of type or location. The hemostatic efficacy of efanesoctocog alfa for the treatment of bleeding episodes was rated as excellent or good for nearly all evaluated first injections (97%). No inhibitors or unexpected safety findings were reported. CONCLUSION: Once-weekly prophylaxis with efanesoctocog alfa provided high-sustained FVIII levels and highly effective bleed treatment and prevention in previously treated children aged <12 years with severe hemophilia A.
引用
- Malec L, Mathias M, Dunn AL, et al. Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial. J Thromb Haemost. 2025. PMID: 40701256. doi:10.1016/j.jtha.2025.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。